Ketanserin in essential hypertension: a double-blind, placebo-controlled study

Cameron, H A; Ramsay, LE

doi:10.1136/pgmj.61.717.583

Cited by 25 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the 12 other patients, the effects of ketanserin treatment on blood pressure were similar in the supine and erect positions. Heart rate was reduced on ketanserin treatment compared with placebo, in agreement with previous findings in younger patients [7,8]. Twenty-four hour ECG tapes showed that abnormal rhythms were common in these patients.…”

Section: Resultssupporting

confidence: 90%

A placebo-controlled crossover study of ketanserin in elderly hypertensive patients

McCarthy¹,

McCarthy²,

John³

et al. 1990

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The results of the European Working Party for Hypertension in the Elderly Study showed that treatment of high blood pressure reduced the morbidity and mortality from strokes and myocardial infarction and reduced the incidence of heart failure in elderly patients. The largest number of hypertensive patients are elderly, and it is in this group of patients that the maximum benefit of treatment might be expected. The present study was designed to study in detail the efficacy and tolerability of ketanserin in an elderly population. Seventeen elderly (greater than 70 years) patients with a lying systolic blood pressure of 160 mmHg and/or a diastolic blood pressure of greater than or equal to 90 mmHg were included in the study. For the 12 patients who completed the study, the mean blood pressure was significantly reduced on ketanserin compared with placebo (p less than 0.001) in the supine and erect positions. The mean net changes in blood pressure after 8 weeks were 21/17 mmHg and 23/16 mmHg erect. Heart rate was also significantly reduced (p less than 0.001) by a mean of 8 beats/min lying and 9 beats/min erect. Analysis of ambulatory 24-hour ECG tapes showed no significant effect of ketanserin on heart rhythms. Ketanserin therapy had no significant effect on routine hematology, plasma electrolytes, biochemistry, or urinalysis. Total exchangeable sodium and potassium and body weight were also unchanged. On ketanserin treatment, the overall quality of life score was significantly improved (p = 0.002; analysis of variance on log transformed data) compared with the placebo phase.

show abstract

Section: Resultssupporting

confidence: 90%

A placebo-controlled crossover study of ketanserin in elderly hypertensive patients

McCarthy¹,

McCarthy²,

John³

et al. 1990

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

“…The therapeutic dose of 2 0 4 0 mg twice daily controlled blood pressure over 24 hr, as measured intra-arterially ( Fig. 2) and by ambulatory monitoring Andren et al, 1983;Cameron and Ramsay, 1985;De Lorenzo et al, 1986;Hedner et al, 1983Hedner et al, , 1985Strano et al, 1986;Waal-Manning et al, 1984Wing et al, 1984;and unpublished data].…”

Section: Chronic Antihypertensive and Hemodynamic Effects Comparison mentioning

confidence: 91%

Ketanserin: A novel cardiovascular drug

Symoens

Janssens

1986

Drug Development Research

View full text Add to dashboard Cite

Symoens, J. and M. Janssens: Ketanserin: A novel cardiovascular drug. Drug Dev. Res. 8:159-172, 1986. Extensive clinical investigation has shown that ketanserin is an effective first-line antihypertensive agent with particular advantages in older patients. It has a favorable hemodynamic profile and seems devoid of serious side-effects. Clinical studies in various diseases indicate a gradual improvement of the microcirculation, which is compatible with selective serotonin S2-antagonism. Ketanserin has a favorable influence on several cardiovascular risk factors. Preliminary data suggest that it has vascular protective effects in patients with atherosclerosis.

show abstract

“…22). Ketanserin does not reduce blood pressure below the normal level in normotensive individuals (for published data see 1, 4,26,57,66,289,291).…”

Section: Comparison With Placebo and Optimal Dosementioning

confidence: 99%